2,7-Naphthyridine containing squaric acids of formula (1) are described:
1
wherein
Ar
1
is an optionally substituted 2,7-naphthridin-1-yl group;
L
2
is a covalent bond or a linker atom or group;
Ar
2
is an optionally substituted aromatic or heteroaromatic chain;
Alk is a chain —CH
2
CH(R)—, —CH═C(R)—,
2
in which R is a carboxylic acid (—CO
2
H) or a derivative or biostere thereof;
R
1
is a hydrogen atom or a C
1-6
alkyl group;
L
1
is a covalent bond or a linker atom or group;
Alk
1
is an optionally substituted aliphatic chain;
n is zero or the integer 1;
R
2
is a hydrogen atom or an optionally substituted heteroaliphatic, cycloaliphatic, heterocycloaliphatic, polycycloalphatic, heteropoly-cycloaliphatic, aromatic or heteroaromatic group;
and the salts, solvates, hydrates and N-oxides thereof.
The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells.